Document is current
Any future updates will be listed below
-
Authors
El Garwany, Omar https://orcid.org/0000-0003-2023-435X
Panousis, Nikolaos I. https://orcid.org/0000-0003-2890-5592
Knights, Andrew https://orcid.org/0000-0003-2107-4175
Kumasaka, Natsuhiko https://orcid.org/0000-0002-3557-0375
Imaz, Maria https://orcid.org/0000-0003-1894-8126
Vilarino, Lorena Boquete https://orcid.org/0000-0002-9600-0114
Tsingene, Anthi
Tokolyi, Alex https://orcid.org/0000-0003-4222-7484
Martin, Cristina Cotobal https://orcid.org/0000-0002-5877-2228
Alegbe, Tobi https://orcid.org/0000-0003-1622-0502
Krzak, Monika
Raine, Tim https://orcid.org/0000-0002-5855-9873
Barnett, Alice https://orcid.org/0009-0001-9544-459X
Gomez, Celine
Gaffney, Daniel J. https://orcid.org/0000-0002-1529-1862
Anderson, Carl A. https://orcid.org/0000-0003-1719-7009
-
Funding
Funding for this research was provided by:
Wellcome Trust (206194, 220540/Z/20/A, 108413/A/15/D, WT098503)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (178005)
British Heart Foundation (RG/18/13/33946, CH/12/2/29428, RE/18/1/34212)
DH | National Institute for Health Research (S-BRC-1215-20014, BRC-1215-20014)
- License Information
-
More Information
Article History
Received: 25 July 2023
Accepted: 23 June 2025
First Online: 27 August 2025
Competing interests
: C.A.A. has received research grants or consultancy/speaker fees from Genomics plc, BridgeBio, G.S.K. and AstraZeneca. D.J.G. was an employee of BioMarin and N.I.P. was an employee of G.S.K. at the time the manuscript was submitted. The remaining authors do not declare any competing financial or non-financial interests.
